Deepak Kanojia Selected Research

Neoplasm Metastasis (Metastasis)

1/2022	Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer.
10/2020	Landscape of combination therapy trials in breast cancer brain metastasis.
1/2020	BET inhibition increases βIII-tubulin expression and sensitizes metastatic breast cancer in the brain to vinorelbine.
5/2015	βIII-Tubulin Regulates Breast Cancer Metastases to the Brain.
11/2012	Proteomic profiling of cancer stem cells derived from primary tumors of HER2/Neu transgenic mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Deepak Kanojia Research Topics

Disease

27	Neoplasms (Cancer) 04/2024 - 08/2006
13	Glioma (Gliomas) 01/2023 - 01/2015
12	Breast Neoplasms (Breast Cancer) 10/2023 - 11/2012
11	Brain Neoplasms (Brain Tumor) 10/2023 - 05/2015
6	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 03/2015
6	Carcinogenesis 01/2021 - 08/2006
5	Neoplasm Metastasis (Metastasis) 01/2022 - 11/2012
3	Disease Progression 02/2024 - 10/2020
3	Triple Negative Breast Neoplasms 02/2024 - 01/2022
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2023 - 01/2022
1	Adenocarcinoma 01/2023
1	Squamous Cell Carcinoma of Head and Neck 03/2022
1	Necrosis 01/2020
1	Circulating Neoplastic Cells 12/2019
1	Mouth Neoplasms (Oral Cancer) 01/2018

Drug/Important Bio-Agent (IBA)

5	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2012
4	Phosphotransferases (Kinase)IBA 02/2024 - 01/2022
4	human ERBB2 proteinIBA 01/2022 - 11/2012
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2006
3	Immune Checkpoint InhibitorsIBA 02/2024 - 01/2023
3	CytokinesIBA 02/2024 - 01/2021
3	Trastuzumab (Herceptin)FDA Link 01/2022 - 10/2015
2	Single-Domain AntibodiesIBA 01/2022 - 12/2019
2	AntibodiesIBA 01/2022 - 10/2015
2	tucatinibIBA 01/2022 - 10/2020
2	ChemokinesIBA 01/2021 - 10/2016
2	TubulinIBA 01/2020 - 05/2015
2	AntigensIBA 01/2020 - 10/2018
2	4-Nitroquinoline-1-oxide (4 Nitroquinoline 1 oxide)IBA 12/2019 - 08/2006
2	SurvivinIBA 01/2016 - 09/2015
2	CarcinogensIBA 01/2012 - 08/2006
1	Immunoconjugates (Immunoconjugate)IBA 04/2024
1	CaspasesIBA 10/2023
1	methixene (metixene)FDA Link 10/2023
1	EnzymesIBA 01/2023
1	Checkpoint Kinase 1IBA 01/2023
1	Hyaluronic Acid (Hyaluronan)IBA 01/2023
1	RNA (Ribonucleic Acid)IBA 03/2022
1	signal sequence receptorIBA 01/2022
1	Antidepressive Agents (Antidepressants)IBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2022
1	pertuzumabIBA 01/2022
1	taxaneIBA 01/2022
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2022
1	ErbB Receptors (EGF Receptor)IBA 01/2022
1	InterferonsIBA 01/2021
1	LymphokinesIBA 01/2021
1	InterleukinsIBA 01/2021
1	Tumor Necrosis FactorsIBA 01/2021
1	Capecitabine (Xeloda)FDA Link 10/2020
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2020
1	Amino Acids FDA Link 01/2020
1	Tryptophan (L-Tryptophan)FDA Link 01/2020
1	B7-H1 AntigenIBA 11/2019
1	Lipid NanoparticlesIBA 11/2019
1	LigandsIBA 07/2019
1	Fatty Acid-Binding Protein 7IBA 01/2019
1	IntegrinsIBA 01/2019
1	Therapeutic UsesIBA 07/2017
1	Neoplasm Antigens (Tumor Antigens)IBA 06/2017
1	OsteoprotegerinIBA 10/2016
1	Peptides (Polypeptides)IBA 09/2015
1	NestinIBA 05/2015
1	3-hydroxyphenyltrimethylammoniumIBA 11/2012
1	Keratins (Keratin)IBA 01/2012
1	cholanthreneIBA 08/2006
1	Coal Tar (Estar)IBA 08/2006
1	9,10-Dimethyl-1,2-benzanthraceneIBA 08/2006

Therapy/Procedure

22	Therapeutics 02/2024 - 01/2013
5	Oncolytic Virotherapy 07/2017 - 01/2015
3	Radiotherapy 01/2022 - 01/2016
2	Drug Therapy (Chemotherapy) 01/2022 - 01/2015
1	Cranial Irradiation 01/2022
1	Precision Medicine 01/2022
1	Immunotherapy 11/2019
1	Immunomodulation 10/2017
1	Biological Therapy 01/2016
1	Chemoradiotherapy 03/2015